RWLK REWALK ROBOTICS LTD

Lifeward to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Lifeward to Present at the H.C. Wainwright 26th Annual Global Investment Conference

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions in rehabilitation, and recovery, announced that Larry Jasinski, Chief Executive Officer, will present and host one-on-one meetings with investors at the H.C. Wainwright 26th Annual Global Investment Conference on September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.

The recorded webcast of the Lifeward management presentation will be available starting at 1:30 pm EDT on September 11, 2024 through the Investors section of the Lifeward website or at the following link: . The archived webcast of the presentation will remain accessible for 90 days following the event.

This conference appearance offers an opportunity for Lifeward to showcase its pioneering efforts to deliver breakthrough technology to advance the standard of care for people with physical limitations or disabilities. Lifeward’s portfolio of proven solutions features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the MyoCycle FES bike, and the ReStore Exo-Suit. These groundbreaking solutions span the continuum of care, delivering functional and health benefits in clinical settings as well as in the home and community.

To learn more about the Lifeward mission and product portfolio, please visit .

About Lifeward

Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the MyoCycle FES System, and the ReStore Exo-Suit.

Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward portfolio, please visit .

ReWalk®, ReStore® and Alter G® are registered trademarks of ReWalk Robotics Ltd. (DBA Lifeward) and/or its affiliates.

Lifeward Media Relations Contact:

Kathleen O’Donnell

Vice President, Marketing & New Business Development

E:

Lifeward Investor Contact:

Mike Lawless

Chief Financial Officer

E: 



EN
04/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REWALK ROBOTICS LTD

 PRESS RELEASE

Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expan...

Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton Clinic days offered at Shirley Ryan AbilityLab, the #1 ranked rehabilitation hospital for 35 consecutive years, with the goal of accelerating personal exoskeleton adoption Streamlined pathway from evaluation to real-world use of ReWalk for people living with spinal cord injury (SCI) HUDSON, Mass. and CHICAGO, March 02, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD), a global leader in innovative medical technology designed to transform the lives of people with physic...

 PRESS RELEASE

Lifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilitie...

Lifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilities Designed to Restore Function to Stroke Survivors IP and technology acquisition is expected to be highly accretive and to advance Lifeward’s position as a diversified biomedical innovation companyWill Expand Lifeward’s portfolio beyond lower-limb solutions, creating a differentiated, whole-body neuro-rehabilitation portfolio Will Strengthen long-term strategic networks with neuro-rehabilitation prescribers, rehabilitation networks, and payers HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- L...

 PRESS RELEASE

Lifeward Announces Reverse Share Split

Lifeward Announces Reverse Share Split Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTech innovation company HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, today announced that effective with the open of the market on February 24, 2026, the Company will complete a 1-for-12 reverse split of its ordinary shares. On Janu...

 PRESS RELEASE

Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage...

Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers Aetna joins Humana and United Healthcare in providing Medicare Advantage coverage for beneficiaries who meet medical necessity criteria for the ReWalk Personal Exoskeleton Together, these three national Medicare Advantage insurers represent approximately 16 million beneficiaries across the United States HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global lead...

 PRESS RELEASE

Lifeward Enters Transformative Strategic Investment and Partnership Ag...

Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide Lifeward cash runway to profitability and diversify its portfolio across MedTech and BioTech Lifeward acquires Oramed’s clinical-stage Protein Oral Delivery (POD™) technology adding exposure to a large, long-term Biotech market opportuni...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch